Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients

被引:21
作者
Fayanju, Oluwadamilola M. [1 ,2 ,3 ,4 ,5 ]
Ren, Yi [6 ]
Greenup, Rachel A. [1 ,2 ,3 ]
Plichta, Jennifer K. [1 ,2 ]
Rosenberger, Laura H. [1 ,2 ]
Force, Jeremy [2 ,7 ]
Suneja, Gita [2 ,8 ,9 ]
Devi, Gayathri R. [1 ,2 ]
King, Tari A. [10 ,11 ]
Nakhlis, Faina [10 ,11 ]
Hyslop, Terry [6 ,12 ]
Hwang, E. Shelley [1 ,2 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Box 3513, Durham, NC 27710 USA
[2] Duke Canc Inst, Womens Canc Program, Durham, NC 27710 USA
[3] Duke Univ, Sch Med, Dept Populat Hlth Sci, 215 Morris St, Durham, NC 27701 USA
[4] Duke Univ, Duke Forge, Durham, NC 27710 USA
[5] Durham VA Med Ctr, Dept Surg, 508 Fulton St, Durham, NC 27705 USA
[6] Duke Canc Inst, BioStat Shared Resource, Durham, NC 27710 USA
[7] Duke Univ, Med Ctr, Dept Med, Box 3893, Durham, NC 27710 USA
[8] Duke Univ, Sch Med, Dept Radiat Oncol, Box 3085, Durham, NC 27710 USA
[9] Duke Global Hlth Inst, Durham, NC 27710 USA
[10] Womens Hosp Med Ctr, Dept Surg, Div Breast Surg, Boston, MA 02115 USA
[11] Womens Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
[12] Duke Univ, Sch Med, Dept BioStat & Bioinformat, Box 2717, Durham, NC 27710 USA
关键词
Axillary lymph node dissection; Inflammatory breast cancer; Neoadjuvant; Pathologic complete response; Sentinel lymph node biopsy; Targeted axillary dissection; SENTINEL-LYMPH-NODE; NEOADJUVANT CHEMOTHERAPY; BIOPSY; IDENTIFICATION; TRASTUZUMAB; MULTICENTER; ULTRASOUND; THERAPY; IMPACT; TRIAL;
D O I
10.1007/s10549-020-05529-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Inflammatory breast cancer (IBC) is an aggressive variant for which axillary lymph node (LN) dissection following neoadjuvant chemotherapy (NACT) remains standard of care. But with increasingly effective systemic therapy, it is unclear whether more limited axillary surgery may be appropriate in some IBC patients. We sought to examine whether extent of axillary LN surgery was associated with overall survival (OS) for IBC. Methods Female breast cancer patients with non-metastatic IBC (cT4d) diagnosed 2010-2014 were identified in the National Cancer Data Base. Cox proportional hazards modeling was used to estimate the association between extent of axillary surgery (<= 9 vs >= 10 LNs removed) and OS after adjusting for covariates, including post-NACT nodal status (ypN0 vs ypN1-3) and radiotherapy receipt (yes/no). Results 3471 patients were included: 597 (17.2%) had cN0 disease, 1833 (52.8%) had cN1 disease, and 1041 (30%) had cN2-3 disease. 49.9% of cN0 patients were confirmed to be ypN0 on post-NACT surgical pathology. Being ypN0 (vs ypN1-3) was associated with improved adjusted OS for all patients. Radiotherapy was associated with improved adjusted OS for cN1 and cN2-3 patients but not for cN0 patients. Regardless of ypN status, there was a trend towards improved adjusted OS with having >= 10 (vs <= 9) LNs removed for cN2-3 patients (HR 0.78, 95% CI 0.60-1.01, p = 0.06) but not for cN0 patients (p = 0.83). Conclusions A majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
引用
收藏
页码:207 / 217
页数:11
相关论文
共 27 条
[11]   Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium [J].
Devi, Gayathri R. ;
Hough, Holly ;
Barrett, Nadine ;
Cristofanilli, Massimo ;
Overmoyer, Beth ;
Spector, Neil ;
Ueno, Naoto ;
Woodward, Wendy ;
Kirkpatrick, John ;
Vincent, Benjamin ;
Williams, Kevin P. ;
Finley, Charlotte ;
Duff, Brandi ;
Worthy, Valarie ;
McCall, Shannon ;
Hollister, Beth A. ;
Palmer, Greg ;
Force, Jeremy ;
Westbrook, Kelly ;
Fayanju, Oluwadamilola ;
Suneja, Gita ;
Dent, Susan F. ;
Hwang, E. Shelley ;
Patierno, Steven R. ;
Marcom, P. Kelly .
JOURNAL OF CANCER, 2019, 10 (15) :3344-3351
[12]   The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT) A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB) [J].
Fayanju, Oluwadamilola M. ;
Ren, Yi ;
Thomas, Samantha M. ;
Greenup, Rachel A. ;
Plichta, Jennifer K. ;
Rosenberger, Laura H. ;
Tamirisa, Nina ;
Force, Jeremy ;
Boughey, Judy C. ;
Hyslop, Terry ;
Hwang, Shelley .
ANNALS OF SURGERY, 2018, 268 (04) :591-601
[13]   5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].
Gianni, Luca ;
Pienkowski, Tadeusz ;
Im, Young-Hyuck ;
Tseng, Ling-Ming ;
Liu, Mei-Ching ;
Lluch, Ana ;
Staroslawska, Elzbieta ;
de la Haba-Rodriguez, Juan ;
Im, Seock-Ah ;
Pedrini, Jose Luiz ;
Poirier, Brigitte ;
Morandi, Paolo ;
Semiglazov, Vladimir ;
Srimuninnimit, Vichien ;
Bianchi, Giulia Valeria ;
Magazzu, Domenico ;
McNally, Virginia ;
Douthwaite, Hannah ;
Ross, Graham ;
Valagussa, Pinuccia .
LANCET ONCOLOGY, 2016, 17 (06) :791-800
[14]   Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J].
Gianni, Luca ;
Eiermann, Wolfgang ;
Semiglazov, Vladimir ;
Manikhas, Alexey ;
Lluch, Ana ;
Tjulandin, Sergey ;
Zambetti, Milvia ;
Vazquez, Federico ;
Byakhow, Mikhail ;
Lichinitser, Mikhail ;
Angel Climent, Miguel ;
Ciruelos, Eva ;
Ojeda, Belen ;
Mansutti, Mauro ;
Bozhok, Alla ;
Baronio, Roberta ;
Feyereislova, Andrea ;
Barton, Claire ;
Valagussa, Pinuccia ;
Baselga, Jose .
LANCET, 2010, 375 (9712) :377-384
[15]   Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute [J].
Hance, KW ;
Anderson, WF ;
Devesa, SS ;
Young, HA ;
Levine, PH .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (13) :966-975
[16]   Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer [J].
Hidar, Samir ;
Bibi, Mohamed ;
Gharbi, Olfa ;
Tebra, Sameh ;
Trabelsi, Amel ;
Korbi, Sadok ;
Bouaouina, Nouredine ;
Ben Ahmed, Slim ;
Khai, Hedi .
INTERNATIONAL JOURNAL OF SURGERY, 2009, 7 (03) :272-275
[17]   Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB? [J].
Imeokparia, Folasade O. ;
Hughes, Tasha M. ;
Dossett, Lesly A. ;
Jeruss, Jacqueline S. ;
Chang, Alfred E. ;
Sabel, Michael S. .
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) :3374-3379
[18]  
Inflammatory Breast Cancer, 2019, INFLAMMATORY BREAST
[19]   Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study [J].
Kuehn, Thorsten ;
Bauerfeind, Ingo ;
Fehm, Tanja ;
Fleige, Barbara ;
Hausschild, Maik ;
Helms, Gisela ;
Lebeau, Annette ;
Liedtke, Cornelia ;
von Minckwitz, Gunter ;
Nekljudova, Valentina ;
Schmatloch, Sabine ;
Schrenk, Peter ;
Staebler, Annette ;
Untch, Michael .
LANCET ONCOLOGY, 2013, 14 (07) :609-618
[20]   Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Mamounas, EP ;
Brown, A ;
Anderson, S ;
Smith, R ;
Julian, T ;
Miller, B ;
Bear, HD ;
Caldwell, CB ;
Walker, AP ;
Mikkelson, WM ;
Stauffer, JS ;
Robidoux, A ;
Theoret, H ;
Sovan, A ;
Fisher, B ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2694-2702